Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
CSE: ALEN.U — AI Meets Digital Health (click to learn more) What’s Behind Cannabis Stock HERB? (click to learn more) Eshbal Acquires a 55% Interest in Dare to Be Different Foods (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Heron Therapeautics Inc HRTX

Healthcare Biotechnology
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration... see more

Current News (NDAQ:HRTX)

Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth

GlobeNewswire January 9, 2026

Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)

GlobeNewswire December 4, 2025

Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress

GlobeNewswire November 4, 2025

Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors

GlobeNewswire October 29, 2025

Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

GlobeNewswire October 21, 2025

Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value

PR Newswire August 15, 2025

Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile

PR Newswire August 8, 2025

Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress

PR Newswire August 8, 2025

Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025

PR Newswire August 8, 2025
View More News ››

Opinion & Analysis (NDAQ:HRTX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:HRTX)

Be the first to post on this bullboard.

New Pacific Metals Corp

New Pacific Metals Corp

New Pacific Metals Corp., together with its subsidiaries, engages in the exploration and development of mineral properties in ...
View More »

Podcasts